

References:

1. Halpert, A. G., Olmstead, M. C., & Beninger, R. J. (2002). Mechanisms and abuse liability of the anti-histamine dimenhydrinate. *Neuroscience & Biobehavioral Reviews*, 26(1), 61-67.
2. Huynh, D. A., Abbas, M., & Dabaja, A. (2023, April 29). Diphenhydramine toxicity. *StatPearls*. Retrieved from <https://www.statpearls.com>
3. Patel, J., & Edwards, J. (2024). Treating diphenhydramine overdose: A literature review of currently available treatment methods. *Toxics*, 12(6), 376.
4. Dinwiddie, A. T., Tanz, L. J., & Bitting, J. (2022). Notes from the field: Antihistamine positivity and involvement in drug overdose deaths — 44 jurisdictions, United States, 2019–2020. *Morbidity and Mortality Weekly Report*, 71(41), 1308–1310.
5. Wolfson, A. R., Wong, D., Abrams, E. M., Wasserman, S., & Sussman, G. L. (2022). Diphenhydramine: Time to move on? *The Journal of Allergy and Clinical Immunology: In Practice*, 10(12), 3124–3130.
6. Rector, K., Merchant, S., & Osunkwo, I. (2020). Evaluation of intravenous diphenhydramine use in patients with sickle cell vaso-occlusive crisis. *Hospital Pharmacy*, 56(6).